Dry powder development: Vectura’s BI alternative backed by Pulmatrix

By Flora Southey

- Last updated on GMT


Related tags Chronic obstructive pulmonary disease

Vectura has advanced plans to develop a dry powder inhaler to treat patients with chronic obstructive pulmonary disease (COPD) for the US market.

VR410 (tiotropium bromide) – previously known as PUR0200 – is a generic alternative to Boehringer Ingelheim’s COPD treatment Spiriva HandiHaler. Vectura is developing it under an exclusive license with clinical-stage biopharmaceutical firm Pulmatrix.

Under the agreement, Vectura can develop Pulmatrix’s once-daily, inhalable formulation in combination with one or more other active pharmaceutical ingredients.

Vectura said this will enable the development of future additional combination assets in the US long-acting bronchodilators (LABA) and long-acting muscarinic antagonist (LABA) markets.

In addition, Pulmatrix will help transfer development and manufacturing activities to Vectura, from where the technology can be licensed to other firms.

“Vectura plans to license VR410 and future VR410 assets to partners with capacity to fund the remaining development and commercialisation activities,” ​a Vectura spokesperson told us.

The spokesperson did not disclose which Vectura facility is responsible for VR410’s development.

Inhaler tech abroad

Earlier this year​, Pulmatrix announced it was extending its IP portfolio following the receipt of a European patent for its particle-based drug delivery technology, iSperse.

The technology – covered under patent EP 2410981 B1 – is used to formulate small molecule drugs for inhaled delivery.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more